Trials / Recruiting
RecruitingNCT04324151
Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC
Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 70 (estimated)
- Sponsor
- Hunan Province Tumor Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer
Detailed description
Inclusion criteria: diagnosed with Non-small cell lung cancer EGFR and ALK and ROS1 negative Treatment naive Potentially Resectable identified by MDT
Conditions
Timeline
- Start date
- 2020-03-24
- Primary completion
- 2024-12-24
- Completion
- 2025-03-24
- First posted
- 2020-03-27
- Last updated
- 2024-09-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT04324151. Inclusion in this directory is not an endorsement.